Jozef Ravinger, Peter Uharček
HER2/neu (erbB2) is a transmembrane receptor with tyrosine kinase activity. The aim of this study is the comparison and evaluation of prognostic importance of HER2/neu in breast tumours with other prognostic factors. The group of 135 patients with malignant breast disease is assessed. Data on patients included the age, operation date, histological type of tumour, grading, tumour size, and status of extirpated lymphatic nodules from I and II etage, NPI and FIGO stage, status of estrogene and progestorene receptors, Ki-67, c-erbB2, and the presence of angioinvasion. Median follow-up was 80 months (18-152). In I stage of disease there were 67 patients (49.6 %), in IIA stage 37 (27.4 %), in IIB stage 27 (20.0 %) and in IIIA stage 4 (3 %) patients. HER-2/neu was negative (0.1+) in 76 cases (56.3 %). 59 women (43.7 %) had positive marking. The statistic dependence of HER-2/neu expression on the tumour size did not confirm statistical difference in survival of patients with negative finding of HER-2/neu.